Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3757316 | 0.90 | GLS (0.49) | CHRM2MEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL1860103 | 0.81 | CHRM2 (0.54) | CHRM2MEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL10898704 | 0.81 | CHRM2 (0.48) | CHRM2MEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL918303 | 0.78 | TDP1 (0.51) | CYP1A2CYP2C19TDP1L3MBTL1MAPT | |
| SCHEMBL30173785 | 0.78 | GLS (0.55) | CHRM2MEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL2286757 | 0.78 | TDP1 (0.51) | CHRM2MEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL3418095 | 0.78 | GLS (0.55) | CHRM2MEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL1863859 | 0.77 | MAOB (0.52) | CHRM2MEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL2284215 | 0.77 | TDP1 (0.50) | CHRM2MEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL5839787 | 0.77 | TDP1 (0.54) | CHRM2MEN1CYP1A2CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2238119-B1 | Quinazolines and related heterocyclic compounds, and their therapeutic use | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIËNTENZORG (NL) | 2015-11-25 | — | — | EP | disclosed |
| US-8530486-B2 | Quinazolines and related heterocyclic compounds, and their therapeutic use | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2013-09-10 | — | — | US | disclosed |
| US-7910611-B2 | Therapeutic agent for restenosis | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-03-22 | — | — | US | disclosed |
| US-20100298322-A1 | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use | VERENIGING VOOR CHRISTELIJK, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2010-11-25 | — | — | US | disclosed |
| US-20100029625-A1 | Therapeutic Agent for Restenosis | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2077263-A1 | Quinazolines and related heterocyclic compounds and their therapeutic use | Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg (NL) | 2009-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298322-A1 | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use | RXFP3, RXFP1, NR1I3 | CHRM2 23/4885MEN1 1483/4885CYP1A2 373/4885 |
| US-20100029625-A1 | Therapeutic Agent for Restenosis | NR1H2, NR1H3, LDLR | CHRM2 1264/4885MEN1 4098/4885CYP1A2 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.